Exclusive Content Related to 2025's Summit
Browse our selection of industry insights from our speakers, previous presentations and exclusive market reports.
Interview with Vicore Pharma Holding's Chief Executive Officer
The field continues to struggle with limited efficacy and tolerability of current treatments, and a lack of therapies that can truly reverse disease progression.
At Vicore, we’re advancing buloxibutid, a first-inclass AT2 receptor agonist that activates lung repair mechanisms upstream of fibrosis with the support of the entire community to execute our global Phase 2b study of this compound. We hope that this study will reveal the ability of a differentiated approach to this disease to drive a breakthrough in patient outcomes.
Interview with Senisca Ltd's Chief Scientific Officer & Founder
I’m excited about the breadth of work happening in the IPF space right now. It feels hopeful. In addition to the work we are doing at SENISCA, the emergence of new targets such as TNIK and IL-11 inhibitors raise hope that we might be able to produce new interventions that are disease modifying.
At SENISCA, we are trying to deal with IPF at its roots by reprogramming old and misbehaving cells back to something more functional. We have a pretty unique way of doing this. I hope that people will take away from my presentation that we are doing something different and exciting!
Explore the Brand-New Agenda
Hear the latest industry updates and gain exclusive insights during our packed discussion-led agenda.
Partner With the IPF Summit
Position yourself alongside other leading solution providers to ensure your brand is directly in front of IPF, ILD & PPF decision makers.
Join An Intimate Community Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during dedicated networking sessions.